

- Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. *Expert Opin Drug Saf* 2006;5:791–809.
- Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. *Expert Rev Anticancer Ther* 2006;6:1249–1269.
- Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med* 1979;91:710–717.
- Aviles A, Arevila N, Diaz Maqueo JC, et al. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. *Leuk Lymphoma* 1993;11:275–279.
- Eidem BW. Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough. *J Am Soc Echoardiogr* 2008;21:1290–1292.
- Oberholzer K, Kunz RP, Dittrich M, et al. [Anthracycline-induced cardiotoxicity: cardiac MRI after treatment for childhood cancer]. *Rofo* 2004;176:1245–1250.
- Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. *Ann Oncol* 2002;13:503–512.
- Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol* 2005;23:2629–2636.
- Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. *Br J Cancer* 2002;86:1697–1700.
- Lunning MA, Kutty S, Rome ET, et al. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy. *Am J Clin Oncol* 2013 [Epub ahead of print].
- Mitani I, Jain D, Joska TM, et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiography in the current era. *J Nucl Cardiol* 2003;10:132–139.
- Suter TM, Meier B. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel? *Ann Oncol* 2002;13:647–649.
- van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. *Cochrane Database Syst Rev* 2010;5:CD005006.
- van Dalen EC, van der Pal HJ, Caron HN, et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. *Cochrane Database Syst Rev* 2009;4:CD005008.
- Swain SM, Ehaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J Clin Oncol* 1997;15:1318–1332.
- Hensley ML, Hagerly KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. *J Clin Oncol* 2009;27:127–145.
- Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. *Blood* 2007;109:896–904.
- Menna P, Paz OG, Chello M, et al. Anthracycline cardiotoxicity. *Expert Opin Drug Saf* 2012;11:S21–S36.
- Miranda CJ, Makui H, Soares RJ, et al. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. *Blood* 2003;102:2574–2580.
- Thompson KL, Rosenzweig BA, Zhang J, et al. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. *Cancer Chemother Pharmacol* 2010;66:303–314.
- Lightfoot JC, D'Agostino RB Jr, Hamilton CA, et al. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. *Circ Cardiovasc Imaging* 2010;3:550–558.
- Morandi P, Ruffini PA, Benvenuto GM, et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 gm²) cyclophosphamide. *Bone Marrow Transplant* 2001;28:277–282.
- Schrama JG, Holtkamp MJ, Baars JW, et al. Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. *Br J Cancer* 2003;88:1831–1838.
- Morandi P, Ruffini PA, Benvenuto GM, et al. Cardiac toxicity of high-dose chemotherapy. *Bone Marrow Transplant* 2005;35:323–334.
- Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. *Ann Intern Med* 1993;118:31–36.
- Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. *Ann Oncol* 2002;13:710–715.
- Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. *J Natl Cancer Inst Monogr* 1993;15:117–130.
- Giordano SH, Booser DJ, Murray JL, et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. *Clin Cancer Res* 2002;8:3360–3368.
- Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. *Cancer* 2003;97:40–45.
- Gianni L, Dombrowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. *Ann Oncol* 2001;12:1067–1073.
- Tan-Chiu E, Yothers F, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. *J Clin Oncol* 2005;23:7811–7819.
- Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2012;30:3792–3799.
- Salvatorelli E, Menna P, Cascegna S, et al. Paclitaxel and docetaxel stimulation of doxorubicin formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. *J Pharmacol Exp Ther* 2006;318:424–433.
- Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. *Tumori* 1982;68:505–510.
- Tsavaris N, Kosmas C, Vadiaka M, et al. 5-Fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study. *J BUON* 2005;10:205–211.
- Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folic acid in patients with gastrointestinal cancer. *Cancer* 1993;72:2242–2247.
- Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. *Ann Oncol* 2002;13:484–485.
- Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. *Cancer Res* 1993;53:3028–3033.
- Cwikiel M, Eskilsson J, Wieslander JB, et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. *Scanning Microsc* 1996;10:805–818, discussion 819.
- Sasson Z, Morgan CD, Wang B, et al. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. *Can J Cardiol* 1994;10:861–864.
- Sudhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasoconstrictions. *Ann Oncol* 2004;15:661–664.
- Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. *Cancer Chemother Pharmacol* 2006;58:487–493.
- de Azambuja E, Bedard PL, Suter T, et al. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? *Target Oncol* 2009;4:77–88.
- Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. *Nat Med* 2002;8:459–465.
- Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. *Proc Natl Acad Sci U S A* 2002;99:8880–8885.
- Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. *Drug Saf* 2008;31:459–467.
- Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. *J Clin Oncol* 2002;20:1215–1221.
- Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol* 2005;23:7820–7826.
- Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. *Clin Cancer Res* 2014;20:15–20.
- Kilickap S, Yazu B, Aksoy S, et al. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. *Med Oncol* 2008;25:437–442.
- Garypidou V, Perifanis V, Tziomalos K, et al. Cardiac toxicity during rituximab administration. *Leuk Lymphoma* 2004;45:203–204.
- Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. *Am J Health Syst Pharm* 2003;60:1531–1548.
- Leach JE. Effect of roentgen therapy on the heart: clinical study. *Arch Intern Med* 1943;72:715.
- Cohn KE, Stewart JR, Fajardo LF, et al. Heart disease following radiation. *Medicine* 1967;46:281–298.
- Arsenian MA. Cardiovascular sequelae of therapeutic thoracic radiation. *Prog Cardiovasc Dis* 1991;33:299–311.
- Adams MJ, Lipshutz SE, Schwartz C, et al. Radiation-associated cardiovascular disease: manifestations and management. *Semin Radiat Oncol* 2003;13:346–356.
- Mauch P, Kalish L, Marcus KC, et al. Long-term survival in Hodgkin's disease. *Cancer J Sci Am* 1995;1:33–42.
- Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. *JAMA* 1993;270:1949–1955.
- Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. *J Clin Oncol* 1993;11:1208–1215.

60. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. *Radiother Oncol* 1998;46:51–62.
61. Aleman BM, van del Belt-Dusebout AW, De Bruin M, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood* 2007;109:1878–1886.
62. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. *JAMA* 2003;290:2831–2837.
63. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. *J Clin Oncol* 2007;25:43–49.
64. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. *J Natl Cancer Inst* 2007;99:206–214.
65. Boice JD Jr. An affair of the heart. *J Natl Cancer Inst* 2007;99:186–187.
66. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst* 2007;99:365–375.
67. Gagliardi G, Lax I, Rutquist LE. Partial irradiation of the heart. *Semin Radiat Oncol* 2001;11:224–233.
68. Stewart JR. Normal tissue tolerance irradiation of the cardiovascular system. *Front Radiat Ther Oncol* 1989;23:302–309.
69. Loyer EM, Delpassand ES. Radiation-induced heart disease: imaging features. *Semin Roentgenol* 1993;28:321–332.
70. Ruckdeschel JC, Chang P, Martin RC, et al. Radiation-related pericardial effusions in patients with Hodgkin's disease. *Medicine (Baltimore)* 1975;54:245–259.
71. Blayney DW, Longo D. Radiation-induced pericarditis. *N Engl J Med* 1982;306:550.
72. Loyer EM, Delpassand ES. Radiation-induced heart disease: imaging features. *Semin Roentgenol* 1993;28:321–332.
73. Gottdeiner JS, Katin MJ, Borer JS, et al. Late cardiac effects of therapeutic mediastinal irradiation. Assessment by echocardiography and radionuclide angiography. *N Engl J Med* 1983;308:569–572.
74. Ni Y, von Segesser LK, Turina M. Futility of pericardiectomy for postirradiation constrictive pericarditis? *Ann Thorac Surg* 1990;49:445–448.
75. Savage DE, Constine LS, Schwartz RG, et al. Radiation effects of left ventricular function and myocardial perfusion in long-term survivors of Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1990;19:721–727.
76. Lagrange JL, Darcourt J, Benoliel J, et al. Acute cardiac effects of mediastinal irradiation: assessment by radionuclide angiography. *Int J Radiat Oncol Biol Phys* 1992;22:897–903.
77. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. *J Clin Oncol* 2004;22:3139–3148.
78. Hequet Q, Le QH, Mouillet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. *J Clin Oncol* 2004;22:1864–1871.
79. Glanzmann C, Huguenin P, Lutolf UM, et al. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. *Radiother Oncol* 1994;30:43–54.
80. Hoge TJ, Ballonoff A, Rusthoven KE, et al. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a Surveillance, Epidemiology, and End-Results analysis. *Int J Radiation Oncol Biol Phys* 2010;76:845–849.
81. Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. *J Am Coll Cardiol* 2003;42:743–749.
82. Slama MS, LeGuludec D, Sebagn C, et al. Complete atrioventricular block following mediastinal irradiation: a report of six cases. *Pacing Clin Electrophysiol* 1991;14:1112–1118.
83. Wethal T, Lund MB, Evarsdn T, et al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. *Br J Cancer* 2009;101:575–581.
84. Byrd BF III, Mendes LA. Cardiac complications of mediastinal radiotherapy. The other side of the coin. *J Am Coll Cardiol* 2003;42:750–751.
85. Gustavsson A, Eskilsson J, Landberg T, et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. *Ann Oncol* 1990;1:355–363.
86. Lund MB, Kongerud J, Boe J, et al. Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? *Ann Oncol* 1996;7:257–264.
87. Marbach JR, Sontag MR, Van DJ, et al. Management of radiation oncology patients with implanted cardiac pacemakers: report of AAPM Task Group No. 34: American Association of Physicists in Medicine. *Med Phys* 1994;21:85–90.
88. Souliman SK, Christie J. Pacemaker failure induced by radiotherapy. *Pacing Clin Electrophysiol* 1994;17:270–273.
89. Last A. Radiotherapy in patients with cardiac pacemakers. *Br J Radiol* 1998;71:4–10.
90. Mouton J, Haug R, Bridier A, et al. Influence of high-energy photon beam irradiation on pacemaker operation. *Phys Med Biol* 2002;47:2879–2893.
91. Barker JE, Fish BL, Su J, et al. 10 Gy total body irradiation increases risk of coronary sclerosis, degradation of heart structure and function in rat model. *Int J Radiat Biol* 2009;85:1089–1100.
92. Hoving S, Heeneman S, Gijbels MJ, et al. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. *Int J Radiat Oncol Biol Phys* 2008;71:848–857.
93. McEniery PT, Dorosti K, Schiavone WA, et al. Clinical and angiographic features of coronary artery disease after chest irradiation. *Am J Cardiol* 1987;60:1020–1024.
94. Yahalom J, Hasin Y, Fuks Z. Acute myocardial infarction with normal coronary arteriogram after mantle field radiation therapy for Hodgkin's disease. *Cancer* 1983;52:637–641.
95. Handler CE, Livesey S, Lawton PA. Coronary ostial stenosis after radiotherapy: angioplasty or coronary artery surgery? *Br Heart J* 1989;61:208–211.
96. Grollier G, Commeau P, Mercier V, et al. Post-radiotherapeutic left main coronary ostial stenosis: clinical and histological study. *Eur Heart J* 1988;9:567–570.
97. Boivin JF, Hutchison GB, Lubin JH, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. *Cancer* 1992;69:1241–1247.
98. Aviles A, Neri N, Nambo MJ, et al. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. *Leuk Lymphoma* 2005;46:1023–1028.
99. Campbell BA, Hornby C, Cunningham J, et al. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. *Ann Oncol* 2012;23:1259–1266.
100. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. *Radiother Oncol* 1999;51:35–42.
101. Jones JM, Ribeiro CG. Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy. *Clin Radiol* 1989;40:204–208.
102. Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst* 2007;99:365–375.
103. Haybittle JL, Brinkley D, Houghton J, et al. Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. *BMJ* 1989;298:1611–1614.
104. Darby SC, McCale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy breast cancer: prospective cohort study of about 300,000 women in US SEER registries. *Lancet Oncol* 2005;6:557–565.
105. Giordano SH, Juo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. *J Natl Cancer Inst* 2005;16:419–424.
106. Hurkmans CW, Borger JH, Bos LJ, et al. Cardiac and lung complication probabilities after breast cancer irradiation. *Radiother Oncol* 2000;55:145–151.
107. Chhalibafian M, Beaudre A, Girinsky T. Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: dose constraints to virtual volumes or to organs at risk? *Radiother Oncol* 2008;87:82–88.
108. Myrehaug S, Pintilie M, Yun L, et al. Population-based study of cardiac morbidity among Hodgkin lymphoma patients with pre-existing heart disease. *Blood* 2010;116:2237–2240.
109. Marks LB, Hebert ME, Bentel G, et al. To treat or not to treat the internal mammary nodes: a possible compromise. *Int J Radiat Oncol Biol Phys* 1994;29:903–909.
110. Stegman LD, Beal KP, Hunt MA, et al. Long-term clinical outcomes of whole-breast irradiation delivered in the prone position. *Int J Radiat Oncol Biol Phys* 2007;68:73–81.
111. Landau D, Adams EJ, Webb S, et al. Cardiac avoidance in breast radiotherapy: a comparison of simple shielding techniques with intensity-modulated radiotherapy. *Radiother Oncol* 2001;60:247–255.
112. Hjal T, Fournier-Bidoz N, Castro-Pena P, et al. Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomography and three-dimensional conformal radiotherapy. *Radiother Oncol* 2010;94:300–306.
113. Borst GR, Sonke JJ, den Hollander S, et al. Clinical results of image-guided deep inspiration breath hold breast irradiation. *Int J Radiat Oncol Biol Phys* 2010;78:1345–1351.
114. Kirova YM. Recent advances in breast cancer radiotherapy: Evolution or revolution, or how to decrease cardiac toxicity? *World J Radiol* 2010;2:103–108.
115. Demirci S, Nam J, Hubbs JL, et al. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. *Int J Radiat Oncol Biol Phys* 2009;73:980–987.
116. MacDonald SM, Patel SA, Hickey S, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. *Int J Radiat Oncol Biol Phys* 2013;86:484–490.
117. Shapiro CL, Hardenbergh PH, Gelman R, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. *J Clin Oncol* 1998;16:3493–3501.
118. Lederman GS, Sheldon TA, Chaffey JT, et al. Cardiac disease after mediastinal irradiation for seminoma. *Cancer* 1987;60:772–776.
119. Savage DE, Constine LS, Schwartz RG, et al. Radiation effects on left ventricular function and myocardial perfusion in long-term survivors of Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1990;19:721–727.
120. Reber D, Birnbaum DE, Tollenaere P. Heart disease following mediastinal irradiation: surgical management. *Eur J Cardiothorac Surg* 1995;9:202–205.
121. Henry-Amar M, Hayat M, Meerwaldt JH. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. *Int J Radiat Oncol Biol Phys* 1990;19:1155–1157.
122. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. *Br J Haematol* 2011;154:23–31.
123. Carver JR, Szalda D, Ky B. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. *Semin Oncol* 2013;40:229–238.